Parkinson's Disease
Gordon Research Conference

June 25-30, 2017
Grand Summit Hotel
Newry, ME, USA

20 years of alpha-synuclein in
Parkinson's Disease
September 7-10 2017

Hotel Mare Nostrum
Athens, Greece

MANAGEMENT TEAM

The three founders and Managing Directors of Origenis, Michael Almstetter, Dr. Michael Thormann, and Dr. Andreas Treml initiated and orchestrated the successful management buy-out of the company from Morphochem AG in October 2005.

 

Michael Almstetter


Michael Almstetter studied chemistry at the Technical University of Munich. He wrote his thesis about “Simulation and Optimisation of Multi Component Reactions with the Use of Genetic Algorithms" at the Organic Chemistry department of Prof. Dr. Ivar Ugi. He applied these theories in an internship at Roche AG. Michael Almstetter laid the fundaments for the later MOREsystem® with the invention of MolMind® as Head of Discovery Chemistry at Morphochem AG. He applied MOREsystem® to a variety of drug discovery projects with success. At Origenis he is responsible for the development and implementation of parallel chemistry, automated synthesis and analytics.

 

Dr. Michael Thormann


Michael Thormann received his Ph.D. in biochemistry from the University of Leipzig in 1998. He worked in the field of secondary structure design and conformational analysis of special non-natural peptides. He held several post-doctoral positions at the University of Barcelona and Polytechnical University of Catalonia. He invented protein- and ligand-based drug design methods, QSPR, parallel evolutionary search algorithms, and multiparametric optimisation techniques for the proprietary MOREsystem® as Head of Molecular Modelling at Morphochem AG. At Origenis, he is responsible for the computer-aided method development, implementation, and application for MOREsystem®.

 

Dr. Andreas Treml


Andreas Treml received his Ph.D. in biology from the University of Regensburg in 1997. He worked in the field of therapeutic oncology and characterized the mode of action of novel nonsteroidal antiestrogens on steroid hormone receptors and the involvement of further transcription factors. Prior to Origenis he developed the high throughput facilities of Morphochem AG where he was responsible for assay development and adaptation for parallel library testing. He also developed the automated HTSS® (high throughput secondary screening) which plays an important role for compound profiling using the MOREsystem®. As one of the inventors of the proprietary MOREsystem®, he is responsible for the integration of biological screening and compound characterization into the interdisciplinary process.